Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$21.36
-2.4%
$20.05
$11.45
▼
$22.13
$7.62B1.243.72 million shs1.63 million shs
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
$7.35
$7.29
$3.27
▼
$7.45
$2.73B1.5413.29 million shsN/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$135.68
+1.3%
$165.57
$123.00
▼
$260.19
$7.05B0.861.16 million shs639,748 shs
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$64.98
-4.1%
$100.01
$28.66
▼
$126.38
$7.42B0.541.37 million shs950,372 shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
-2.37%-1.56%+7.67%+19.27%+85.43%
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
0.00%0.00%0.00%-0.41%+92.41%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
+1.25%-6.02%-14.98%-34.70%-7.56%
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
-4.15%-11.84%-44.20%-46.85%-14.61%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$21.36
-2.4%
$20.05
$11.45
▼
$22.13
$7.62B1.243.72 million shs1.63 million shs
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
$7.35
$7.29
$3.27
▼
$7.45
$2.73B1.5413.29 million shsN/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$135.68
+1.3%
$165.57
$123.00
▼
$260.19
$7.05B0.861.16 million shs639,748 shs
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$64.98
-4.1%
$100.01
$28.66
▼
$126.38
$7.42B0.541.37 million shs950,372 shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
-2.37%-1.56%+7.67%+19.27%+85.43%
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
0.00%0.00%0.00%-0.41%+92.41%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
+1.25%-6.02%-14.98%-34.70%-7.56%
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
-4.15%-11.84%-44.20%-46.85%-14.61%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
2.80
Moderate Buy$23.007.67% Upside
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
2.07
Hold$10.5643.62% Upside
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.86
Moderate Buy$266.2196.20% Upside
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
2.50
Moderate Buy$139.50114.68% Upside

Current Analyst Ratings Breakdown

Latest ATAI, CORT, AXSM, and AMRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/13/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Lower Price TargetEqual Weight$249.00 ➝ $223.00
11/10/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
DowngradeBuy (B) ➝ Hold (C+)
11/5/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
Boost Price TargetOutperform$23.00 ➝ $25.00
11/4/2026
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
UpgradeHold (C) ➝ Hold (C+)
11/4/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
Reiterated RatingOverweight$21.00
11/4/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
Boost Price TargetOverweight$24.00 ➝ $25.00
11/4/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Lower Price TargetOutperform$284.00 ➝ $272.00
11/4/2026
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
Reiterated RatingOverweight$165.00 ➝ $173.00
11/3/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Reiterated RatingOutperform
11/3/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Lower Price TargetBuy$256.00 ➝ $239.00
11/3/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetEqual Weight$247.00 ➝ $249.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$3.02B2.47$1.52 per share14.01$1.52 per share14.05
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
$4.09M666.46N/AN/A$0.69 per share10.65
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$638.50M11.18N/AN/A$2.00 per share67.84
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$761.41M9.34$0.87 per share75.09$7.62 per share8.53
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$72.06M$0.4223.0318.902.494.17%283.50%7.79%N/A
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
-$660.05M-$2.18N/AN/AN/A-14,938.36%-88.30%-58.88%N/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$183.17M-$3.06N/A37.07N/A-18.18%-198.73%-22.03%N/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$99.65M$1.2753.3817.85N/A16.53%22.56%17.83%N/A

Latest ATAI, CORT, AXSM, and AMRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/3/2026Q3 2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$0.23$0.26+$0.03-$0.06N/A$862.68 million
11/3/2026Q3 2026
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$0.84$1.01+$0.17$1.01$339.13 million$340.47 million
11/2/2026Q3 2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.6343-$0.25+$0.3843-$0.25$249.19 million$259.69 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
N/AN/AN/AN/AN/A
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
N/AN/AN/AN/AN/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
5.61
1.87
1.24
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
N/AN/AN/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
1.21
1.42
1.34
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/A
3.00
2.94

Institutional Ownership

CompanyInstitutional Ownership
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
31.82%
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
28.41%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
93.61%

Insider Ownership

CompanyInsider Ownership
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
17.30%
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
19.80%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
20.60%
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
20.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
8,500348.41 million288.14 millionOptionable
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
80370.86 million297.43 millionOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
92552.60 million41.76 millionOptionable
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
730109.44 million86.79 millionOptionable

Recent News About These Companies

What Is Driving The Move In Corcept Therapeutics Stock?
Corcept Therapeutics (CORT) Gets a Buy from Canaccord Genuity

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amneal Pharmaceuticals stock logo

Amneal Pharmaceuticals NASDAQ:AMRX

$21.36 -0.52 (-2.37%)
Closing price 11/19/2026 03:59 PM Eastern
Extended Trading
$21.26 -0.10 (-0.47%)
As of 04:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Atai Beckley stock logo

Atai Beckley NASDAQ:ATAI

Atai Beckley N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. Atai Beckley N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$135.68 +1.68 (+1.25%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$135.14 -0.55 (-0.40%)
As of 04:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Corcept Therapeutics stock logo

Corcept Therapeutics NASDAQ:CORT

$64.98 -2.81 (-4.15%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$63.90 -1.09 (-1.67%)
As of 04:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.